HC Wainwright Reaffirms “Buy” Rating for Atyr PHARMA (NASDAQ:ATYR)

HC Wainwright reaffirmed their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $35.00 price objective on the stock.

ATYR has been the topic of several other reports. Jefferies Financial Group started coverage on shares of Atyr PHARMA in a research note on Thursday, September 5th. They issued a “buy” rating and a $9.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Atyr PHARMA in a research report on Wednesday, August 14th. Finally, Wells Fargo & Company initiated coverage on shares of Atyr PHARMA in a research report on Friday, October 4th. They issued an “overweight” rating and a $17.00 price target for the company.

Atyr PHARMA Stock Performance

Shares of ATYR stock opened at $3.27 on Tuesday. The firm has a market capitalization of $274.49 million, a PE ratio of -3.48 and a beta of 1.07. Atyr PHARMA has a fifty-two week low of $1.14 and a fifty-two week high of $3.80. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $2.88.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, research analysts forecast that Atyr PHARMA will post -0.89 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.